Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers

Chemosaturation or percutaneous hepatic perfusion (CS-PHP) with melphalan represents a regional therapy strategy for unresectable primary or secondary intrahepatic malignancies. A randomized controlled phase III trial assessed the efficacy of CS-PHP in patients with liver metastases of cutaneous or ocular melanoma (OM) [1]. Treatment with CS-PHP was associated with superior prolonged median hepatic progression-free survival (hPFS; 7 vs. 1.6 months, respectively) and improved hepatic objective response compared to best alternative care. These encouraging results are supported by other small, non-randomized studies in OM patients [1‐3]. CS-PHP also showed response in some patients with hepatic metastases from neuro-endocrine tumors, sarcomas, and various types of carcinomas [1‐10]. Moreover, the safety of CS-PHP and promising outcomes in a patient population with primary or secondary tumors were recently demonstrated in a single-center study [11]. Although CS-PHP treatment seems to carry a significant benefit for some patients, the optimal frequency, safety, and the tolerability of CS-PHP treatment repetition are undefined. Thus, most patients reported in the present studies received in general a minimum of two cycles of CS-PHP [6, 12]. We are interested in the question of whether CS-PHP planned from the outset as a repeat treatment is a more effective approach to the long-term treatment of suitable patients. Therefore, based on the decision of the tumor board, sequential treatments were performed in eligible patients at our center.

Accordingly, between 01/2016 and 12/2019, 13 patients with OM, CCA, or hepatocellular carcinoma (HCC) were treated with CS-PHP at our center, and 10 of them received multiple treatments, with a minimum of two CS-PHP procedures and on which we want to focus in this work. Prerequisites for CS-PHP treatment were sufficient hematologic, renal, and hepatic function and consent of the patient, as well as an Eastern Cooperative Oncology Group (ECOG) 0–1. Significant arterial hepatico-enteric anastomoses were embolized to prevent systemic exposure to melphalan during angiographic evaluation up to 14 days prior to CS-PHP. Before administration of melphalan, a venogram was obtained through the injection port of the double-balloon catheter to exclude leakages [13]. Patients received CS-PHP under general anesthesia and with systemic anticoagulation using the Hepatic CHEMOSAT® Delivery System (Delcath Systems, Inc., NY, the USA) according to the manufacturer’s recommendations [7].

In total, 45 CS-PHPs were performed in 13 patients with a maximum of 6 treatments per patient. Nine patients had unresectable intrahepatic metastases of OM, two of which also had tumor pulmonary tumor manifestations, peritoneal carcinomatosis (n = 1), osseous (n = 1), subcutaneous (n = 2), or cerebral metastasis (n = 1). Two patients with CCA received the initial CS-PHP treatment and one another three subsequent treatments. The HCC patient received 6 CS-PHP treatments as an individual case decision, because of intolerance to tyrosine kinase inhibitors and that immune checkpoint therapy was not sufficiently established at the time of the treatment interval. Three patients with only one CS-PHP treatment were excluded for the analysis. Patient 3 and 13 showed a fulminant hepatic tumor progression after the first CS-PHP and died due to too rapid tumor progression. Patient 11 suffered from severe symptoms of liver cirrhosis and died because of esophageal varices bleeding due to portal hypertension caused by portal vein thrombosis (Fig. 1).

At the time of data collection, six out of ten patients were in medical follow-up for a median duration of 361 (range, 284–585) days from first CS-PHP and 1602 (range, 643–2104) days from first diagnosis of primary malignant disease. A total of four patients died within the observation period. Three patients died despite intrahepatic tumor response from cardio-vascular events (patient 1), cerebral OM metastasis (patient 2), or liver function loss following a transarterial radio-embolization, which was conducted due to the patient’s preference about one year since the last CS-PHP treatment (patient 12). Patient 8 died early after the second CS-PHP treatment due to rapid tumor progression. No cases of deaths were directly linked to CS-PHP treatment.

The ORR to CS-PHP according to tumor decrease by mRECIST criteria was 80%, including seven patients with OM and the one with CCA assessed at first re-staging date 8–10 weeks after treatment. Stable intrahepatic disease was achieved in one patient with HCC (patient 10) over a duration of 20 months.

The median hPFS for OM patients was 336 (range, 0–354) days. The hepatic tumor burden in the single HCC patient was stable during the entire observation period of 356 days, and no extrahepatic progress was detected. The hPFS for the CCA patient was 251 days.

The median OS of the overall population was 421 (range, 153–701) days from first CS-PHP. The OM patients showed a median OS of 391 (range, 153–523) days from first CS-PHP.

CS-PHP induced massive tumor shrinkage in individual patients, as demonstrated in a 30-year-old female (patient 2) with multiple hepatic OM metastases with a diameter of up to 10 cm. The tumor burden showed a strong decrease of 50% and 43% after the first and second CS-PHP treatment, respectively, and the tumor extension remained stable over 13 months (Fig. 2A). Another OM patient showed stable disease over 6 CS-PHP treatments (patient 10). In another patient (patient 4) with multiple hepatic OM metastases, complete response was found after 4 CS-PHP treatments (Fig. 2B). Finally, only one OM patient who initially showed response to CS-PHP had intrahepatic tumor progression after the fourth CS-PHP treatment, 7 months after first CS-PHP.

Adverse events associated with CS-PHP were classified according to the Common Terminology Criteria for adverse events (CTCAEv4.03). A total of 96 adverse events (AEs) were reported during the CS-PHP treatments, including 52 classified grade I, 25 grade II, 16 grade III, and three grade IV (Supplement 1). All AEs occurred within 15 days after CS-PHP treatment were transient and, with exception of one case, self-resolving. Thus, no patient suffered a severe side effect directly linked to melphalan application. The majority of AEs were hematologic. In one case (patient 10), neutropenic fever (> 38.5 °C) occurred after the first CS-PHP treatment which was treated with filgrastim and erythropoietin for bone marrow stimulation. During the subsequent 5 CS-PHP treatment, no additional neutropenia occurred. One patient with OM (patient 9) suffered circulatory instability, cardiac and ventilator insufficiency during melphalan administration. However, it is important to point out that a statement about the tolerability in patients with liver cirrhosis cannot be made conclusively.

Over the course of the repeated CS-PHP treatments, a moderate increase in median alanine aminotransferase (ALT) was observed. Median levels of bilirubin remained unchanged, and only some patients showed mild bilirubin increases during CS-PHP repetition (Fig. 3a-b).

Thus, most patients reported in the present studies received in general two cycles of CS-PHP, with the exception of a small group of patients with more than two repetitive treatments [7, 12‐16].The analysis of our long-term approach showed that up to 6 CS-PHP can be well tolerated, in alignment with results of a recently published single-center analysis [11]. Even after multiple repetitions, there was no increase in CS-PHP-related AEs. It therefore seems justified to assume that even more repetitions of CS-PHP treatments as applied in our population would be tolerable in individual patients. Importantly, patients who had initially responded to treatment showed stable disease or further intrahepatic response during subsequent CS-PHP treatments.

Another argument for long-term repetition of CS-PHP deduced from our findings is that the initial decrease in tumor mass seen in all patients showing an initial response to CS-PHP remained stable during the observation period, and continued to further decrease after treatment repetitions, even under the visualization limit.

In summary, our findings are encouraging to study the repetitive long-term use of CS-PHP treatment as a novel therapeutic approach for hepatic OM metastasis. Moreover, also, patients with primary liver tumors might benefit from this treatment. Further studies are warranted to develop CS-PHP as an effective treatment option for primary and secondary liver tumors.